Présentation de l'entreprise
Senti Biosciences, Inc. operates as a clinical stage biotechnology company dedicated to developing cell and gene therapies engineered with proprietary gene circuit platform technologies for patients suffering from incurable diseases. The firm's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to advance its therapeutic pipeline within the competitive biotechnology landscape. Operating within the healthcare sector and the biotechnology industry, the company focuses on high-risk, high-reward research and development phases rather than mature commercialization. As of the latest reporting period, the entity holds a market capitalization of $26.54M and reported total revenue of $22,000 over the trailing twelve months, while the specific count of employees is not disclosed in available data. These valuation and revenue figures indicate that Senti Biosciences functions as a micro-cap entity with negligible current commercial sales, reflecting its status as a pre-revenue or early-stage clinical asset where market value is derived almost exclusively from intellectual property and potential future regulatory approval rather than cash flow generation.
Santé financière
The company recorded revenue of $22,000 over the trailing twelve months, yet simultaneously reported a net income loss of $61,438,000 and an EBITDA of $-54,667,000. The substantial gap between the minimal revenue of $22,000 and the massive net loss of $61,438,000 reveals an operational cost structure heavily dominated by research and development expenditures, general administrative costs, and likely share-based compensation typical of clinical-stage biotechs. Free cash flow stands at $-23,338,000, indicating that the company is burning through cash reserves to fund its clinical trials and operational infrastructure without any offsetting commercial cash inflows. This negative cash burn limits financial flexibility, necessitating continued access to capital markets or existing liquidity pools to sustain operations until product candidates advance. Analysis of the three primary margins shows a gross margin of 0.0%, an operating margin of -37095.5%, and a profit margin of 0.0%, figures that collectively signify a business model currently unable to generate profitability from its sales or operations due to the immaturity of the revenue base. The balance sheet presents a leveraged position with total debt of $28.89M against cash and cash equivalents of $16.73M, resulting in a debt-to-equity ratio of 516.93, which implies significant leverage relative to shareholders' equity. Despite the debt exceeding cash holdings, the current ratio of 1.67 suggests that the company maintains a liquidity buffer where current assets exceed current liabilities by a margin that may support short-term obligations if liquidation occurs quickly. Furthermore, the return on equity is -218.1% and the return on assets is -48.9%, metrics that reveal that management has not yet achieved positive returns on the capital invested in the company, reflecting the inherent risk profile of early-stage biotechnology development.
Évaluation de la valorisation
The trailing twelve-month P/E ratio is not applicable due to the lack of earnings, while the forward P/E is listed as -0.95, implying that analysts or data sources project continued negative earnings or that the current valuation is based on non-traditional metrics given the absence of positive profitability. The price-to-book ratio stands at 4.71, indicating that the market values the company at a significant premium over its net book value, likely driven by the perceived potential of its gene circuit platform technologies rather than tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 1206.28 and the EV/EBITDA of -0.71 suggest that traditional valuation multiples are distorted by the company's lack of revenue scale and negative earnings, making these figures less comparable to mature pharmaceutical firms. The stock has traded within a 52-week range with a high of $5.10 and a low of $0.77, and without a specific current share price provided in the source data, the relative trading position cannot be precisely calculated, though the wide range highlights significant price volatility. The beta value of 2.12 indicates that the stock price is expected to be highly volatile, moving with more than double the magnitude of the broader market index during periods of equity market turbulence.
Growth & Income
Available data indicates that year-over-year revenue growth and earnings growth are not applicable, likely due to the transition from zero or negligible revenue to the reported $22,000, which renders standard growth percentage calculations mathematically undefined or irrelevant for this specific reporting period. For a non-dividend payer, the company does not distribute a dividend yield or payout ratio, meaning all available cash flow is retained to fund operations and research rather than being distributed to shareholders. The absence of a dividend yield of N/A and a payout ratio of 0.0% confirms that the company reinvests all financial resources into its clinical development pipeline rather than providing an income stream to investors. Consequently, the overall growth and income profile of Senti Biosciences is characterized entirely by capital appreciation potential and the risk of dilution or insolvency, with no current component of passive income derived from dividends or earnings distribution.